Behind the Manuscript: The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD

episode

Previously titled “The Psychedelic Renaissance: Long-Term Psilocybin Outcomes for Treatment-Resistant Depression with David Feifel, MD, PhD” — renamed by the publisher on Aug 11, 2026

The Journal of Clinical Psychiatry Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Booked out doesn't mean you're ready for an associate OD 23 min · 23 Sep 2026 · The Optometry Success Podcast

Could sofa theory help you find your ideal partner? 4 min · 23 Sep 2026 · Do you really know?

Behind The Scenes At Vogue World Milano 28 min · 23 Sep 2026 · The Run-Through with Vogue

Is end-to-end encryption really secure? 4 min · 23 Sep 2026 · Do you really know?

Do tongue scrapers actually help with bad breath? 5 min · 23 Sep 2026 · Do you really know?

Lab Notes: Have we found dark matter? 10 min · 23 Sep 2026 · The Science Show

Report any issue

Source

Recorded13 Jan 2026

Publisherfeeds.captivate.fm ↗

Handlerec:15287283

Show notes

Dr. David Feifel, Professor Emeritus of Psychiatry at UC San Diego and founding president of the Kadima Neuropsychiatry Institute, joins the JCP Podcast to kick off the new "Psychedelics in Psychiatry" theme. A pioneer in the field who established the world’s first ketamine infusion program for depression, Dr. Feifel sits down to discuss the paradigm shift currently reshaping mental health care.In this installment of the Behind the Manuscript series, Dr. Feifel breaks down the findings of his recent JCP paper: “Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Depression”. He explains the significance of the 25mg dose in preventing relapse over 52 weeks and offers a critical look at why traditional SSRIs are no longer enough. Beyond the data, the conversation delves into the nuances of "set and setting," the controversy of microdosing versus "heroic" doses, and the practical challenges clinicians face as the field moves toward interventional psychiatry. Dr. Feifel also challenges the traditional medical view of the placebo effect, arguing that harnessing expectation may be the key to the next generation of healing.Episode Highlights:00:00 - Dr. David Feifel and His Breakthrough Career02:13 - How Early Curiosity Led to Psychiatry Instead of Neurology07:33 - Balancing Clinical Practice With Research Innovation11:41 - Psychiatry Entering a Transformational New Era13:51 - Why SSRIs Fall Short and TRD Demands Better Solutions17:27 - What Makes Psilocybin the Leading Psychedelic Candidate20:25 - Why the Psychedelic Renaissance Is Surging Now25:42 - Microdosing Myths and the Power of Expectancy33:55 - How Set and Setting Shape Psychedelic Treatment Outcomes39:51 - Do Psychedelics Really Need Psychotherapy to Work48:58 - Inside the Phase 2 Study and How TRD Patients Were Enrolled56:04 - Why 25mg Psilocybin Delivered the Strongest Clinical Results1:05:39 - What Long-Term Follow Up Reveals About Relapse and Durability1:11:38 - How Clinicians Can Prepare for Psychedelic Medicine Adoption1:16:53 - Why the Future of Psychiatry May Rely on Harnessing Placebo PowerKey Takeaways:"Psychiatry is in the midst of a golden age revolution... I feel like every day I was going to war with Godzilla with a peashooter. Now I feel like we've got some real tools.""We’re in the midst of what I call the Cambrian explosion of treatments... a massive explosion of life forms after a long time of stagnation.""The concept of 'one and done' with psychedelics is dead. We aren't going to have patients come in one time and say, 'You're good for life.'""Doing ketamine is like doing psychotherapy, but you're both the psychotherapist and the patient at the same time."Links:Full transcript and show notes: https://www.psychiatrist.com/jcp/ep6-psychedelic-renaissance-david-feifel/Journal of Clinical Psychiatry: http://psychiatrist.com/jcp/Dr. David Feifel: https://www.linkedin.com/in/davidfeifel/Kadima Neuropsychiatry Institute: https://www.kadimanp.com/“Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder”:

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related